Mednet Logo
HomeMedical OncologyQuestion

What is your approach to tamoxifen use in women who are unable to discontinue a strong CYP2D6 inhibitor and who are unable to use or tolerate an AI?

2 Answers
Mednet Member
Mednet Member
Medical Oncology · Icahn School of Medicine at Mount Sinai

I ran into this very situation not too long ago. In dealing with the situation, I asked myself the following questions: 1) Did I speak to prescribing psychiatrist or psychopharmacologist (or if I was the prescriber or primary care provider refer to a more experienced physician?) 2) Did I do everythi...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida

There is data supporting the equivalency of toremifene in the adjuvant setting (Lewis et al., PMID 20209619). Since it is mostly metabolized through CYP3A4, it may be a good choice in this case.

Register or Sign In to see full answer

What is your approach to tamoxifen use in women who are unable to discontinue a strong CYP2D6 inhibitor and who are unable to use or tolerate an AI? | Mednet